RSV Prevention Tied to Lower Infant Acute Care Use - Summary - MDSpire
From the Journals

RSV Prevention Tied to Lower Infant Acute Care Use

Data suggest fewer respiratory syncytial virus–associated hospitalizations and emergency department visits among the youngest infants during the second season of routine prevention product use.

  • By

  • Andrea Surnit

  • May 5, 2026

  • 5 min

Share

A study in Washington state evaluated the impact of nirsevimab and maternal vaccination on respiratory syncytial virus (RSV) hospitalizations among infants. Conducted between July 2022 and June 2025, the research revealed a 43% reduction in RSV-associated hospitalizations for infants under 7 months in the second year of routine product use. The analysis included over 16,000 instances of RSV-related visits, showing significant population-level effects as coverage increased, although limitations included reliance on diagnosis codes and potential misclassification of data. The study emphasizes the need for tailored guidance for specific racial groups and highlights the role of new treatments like clesrovimab in prevention efforts.

Original Source(s)

RSV Prevention Tied to Lower Infant Acute Care Use

  • by Andrea Surnit

  • May 5, 2026

Related Content

Not All Lung Bacteria Are the Enemy

Cross-disease meta-analysis also found modest associations with lung function, though findings varied by disease type

Preexisting Risk Drove Poststorm Events

Analysis of nearly 1.6 million veterans showed preexisting community health inequities largely explained poststorm cardiovascular and respiratory outcomes.

Former Smokers May Merit Later Screening

Cohort data suggest past-eligible former smokers retain competing mortality profiles similar to younger current-eligible smokers